<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930839</url>
  </required_header>
  <id_info>
    <org_study_id>A10-597</org_study_id>
    <nct_id>NCT00930839</nct_id>
  </id_info>
  <brief_title>Role of Prostaglandins on Niacin-Induced Flushing</brief_title>
  <official_title>Exploring the Role of Prostaglandin D2 and the DP1 Receptor on Nicotinic Acid Induced Flushing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Virginia Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will focus on investigating the nicotinic acid stimulated release of prostaglandin&#xD;
      D2 in normal controls. In subsequent studies, the investigators would like to further explore&#xD;
      this pathway in people with type 2 diabetes. Enhanced blood flow (or flushing) may be&#xD;
      compromised or exaggerated in type 2 diabetes particularly in those with impairment of&#xD;
      autonomic function measured as the respiratory heart rate variability (HRV) of different&#xD;
      frequencies reflecting the balance between the sympathetic and parasympathetic nervous&#xD;
      systems. The investigators hypothesize that the vasodilatory effects induced by nicotinic&#xD;
      acid will be different in glabrous and hairy skin and that autonomic imbalance may alter the&#xD;
      response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose that nicotinic acid (NA) stimulates release of prostaglandin D2&#xD;
      (PGD2). To fully understand this mechanism, the investigators will examine the systemic&#xD;
      release of PGD2 and skin blood flow using laser Doppler (LDF) on the upper and lower limbs of&#xD;
      healthy control subjects. The investigators will quantify and establish the effects of oral&#xD;
      nicotinic acid (NiaspanÂ®) given alone and in combination with aspirin on:&#xD;
&#xD;
        1. skin blood flow using laser Doppler (LDF) of glabrous and hairy skin of the forearm of&#xD;
           healthy subjects&#xD;
&#xD;
        2. the severity and intensity of flushing using a visual analog scale, FAST tool, and&#xD;
           whether aspirin is able to block the flushing response&#xD;
&#xD;
        3. the impact on sympathetic/parasympathetic balance using the various frequencies of heart&#xD;
           rate variability (HRV) which reflect the contribution of the different divisions of the&#xD;
           autonomic nervous system (ANS)&#xD;
&#xD;
        4. circulating levels of PGD2 and other neuropeptides to determine other mediators of the&#xD;
           flushing response. This will allow us to conclude whether this pathway is intact and&#xD;
           explore other non-DP1 vasodilatory mechanisms.&#xD;
&#xD;
        5. Langerhans cell density in epidermis and microvasculature using immunohistochemistry of&#xD;
           Langerin (measured as CD1a) in 3 mm skin biopsies of volar and hairy surfaces of the&#xD;
           forearm and hairy surface of the lateral aspect of proximal lower limb. To date, there&#xD;
           is very little known about the density or distribution of Langerhans cells. The PGD2&#xD;
           receptor DP1 will be examined for its content in the epidermis using&#xD;
           immunohistochemistry or RTPCR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy measures are skin perfusion measurements and neurological measures.</measure>
    <time_frame>30 minutes after administration of Niacin</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary measures include blood chemistries</measure>
    <time_frame>15-30 min serial measurements</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Flushing</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Normal, healthy controls, males and females, ages 30-80</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin and aspirin</intervention_name>
    <description>1000 mg Niacin, 325 mg aspirin</description>
    <arm_group_label>Controls</arm_group_label>
    <other_name>Niaspan</other_name>
    <other_name>Nicotinic acid</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin biopsies and serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Normal, healthy control subjects, males and females, ages 30-80&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy controls ages 30-80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of type 1 diabetes or type 2 diabetes&#xD;
&#xD;
          2. Presence of clinically significant neuropathy, (Dyck stage &gt;2b) defined by abnormal&#xD;
             neurologic testing (neurologic physical exam, nerve conduction, autonomic and&#xD;
             quantitative sensory tests)&#xD;
&#xD;
          3. History of major macrovascular events such as myocardial infarction or stroke within&#xD;
             the past 3 months&#xD;
&#xD;
          4. Participation in another clinical trial concurrently or within 30 days prior to entry&#xD;
             into this study.&#xD;
&#xD;
          5. Uncontrolled or untreated hypothyroidism as evidenced by TSH concentrations &gt;4.8 uU/ml&#xD;
&#xD;
          6. Other serious medical conditions which, in the opinion of the investigator, would&#xD;
             compromise the subject's participation in the study, including sensitivity to aspirin&#xD;
&#xD;
          7. Abnormalities of liver function defined as any liver enzymes (AST, ALT, SGPT, SGOT)&#xD;
             greater than 3 times the upper limit of normal&#xD;
&#xD;
          8. History of NYHA Class IV congestive heart failure.&#xD;
&#xD;
          9. Allergy to Niaspan or aspirin&#xD;
&#xD;
         10. Use of drugs known to affect prostaglandin metabolism such as angiotensin converting&#xD;
             enzyme inhibitors (ACE) inhibitors and angiotensin receptor blockers (ARBs) will be&#xD;
             allowed with stable use for 3 months.&#xD;
&#xD;
         11. Pregnancy or breastfeeding&#xD;
&#xD;
         12. History of peptic ulcer disease&#xD;
&#xD;
         13. Current history of smoking&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron I Vinik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Virginia Medical School, Strelitz Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Virgnia Medical School, Strelitz Diabetes Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510f</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>March 9, 2010</last_update_submitted>
  <last_update_submitted_qc>March 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Aaron I. Vinik, MD, PhD</name_title>
    <organization>Eastern Virginia Medical School, Strelitz Diabetes Center</organization>
  </responsible_party>
  <keyword>Niacin</keyword>
  <keyword>Prostaglandin D2</keyword>
  <keyword>Flushing</keyword>
  <keyword>Nicotinic acid stimulated release of prostaglandin D2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

